FLT3 and acute myeloid leukemia: In the Phase II trial of quizartinib, it improved overall survival in approximately 50% of AML patients [14, 15], but its long-term administration produces AML recurrence, in a part, with quizartinib resistance-conferring mutations of FLT3-ITD.